证券代码：300832 证券简称：新产业 公告编号：2026-002 深圳市新产业生物医学工程股份有限公司 关于持股 5%以上股东权益变动比例触及 1%及 5%整数倍的 提示性公告 持股 5%以上的股东天津红杉聚业股权投资合伙企业（有限合伙）保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、 本次权益变动主要因深圳市新产业生物医学工程股份有限公司（以下简 称"公司"）持股 5%以上的股东天津红杉聚业股权投资合伙企业（有限合伙）（以 下简称"红杉聚业"）通过大宗交易方式减持股份导致红杉聚业持有公司股份比 例发生变化。本次权益变动后，公司股东红杉聚业持有公司股份数量为 78,571,878 股，占公司总股本的 10.00%，权益变动比例触及 1%及 5%的整数倍。 2、 本次权益变动变化不触及要约收购，不会导致公司控股股东、实际控制 人发生变化，不会影响公司的治理结构和持续经营。 公司于近日收到红杉聚业出具的《关于新产业股份权益变动情况的告知函》 《简式权益变动报告书》，根据《上市公司收购管理 ...

Core Viewpoint - The State Administration for Market Regulation (SAMR) reported that out of 2,387 food samples tested, 45 batches were found to be non-compliant with food safety standards, indicating ongoing concerns regarding food safety in the market [2][3]. Summary by Category Non-compliant Food Products - A total of 45 batches of food products were identified as non-compliant, with specific issues related to various food safety standards [2][4]. - Examples of non-compliant products include: - Hand-made vermicelli from Shanxi Province containing non-compliant levels of food colorants [4]. - Red sugar cubes from Sichuan Province with excessive levels of sulfur dioxide [4]. - Grain liquor from Hubei Province with non-compliant levels of sweeteners [4]. - Various products sold online, including health supplements and snacks, with issues ranging from non-compliant colorants to microbial contamination [4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Regulatory Actions - Provincial market regulation departments have initiated investigations and corrective actions regarding the identified non-compliant food products [3]. - The report emphasizes the importance of adhering to food safety standards to protect consumer health and maintain market integrity [2][3].

Core Insights - The establishment of the Advanced Medical Device Industrial Park in Zigong marks a significant breakthrough for the city, which previously lacked a related industrial foundation. The project has progressed from concept to initiation in less than five months, covering an area of over 60 hectares [3][4]. Group 1: Industry Focus and Strategy - Zigong has chosen to enter the advanced medical device sector due to its manageable investment cycle and higher success rate compared to the biopharmaceutical industry. The city has nine tertiary hospitals that can provide valuable clinical trial and application scenarios for enterprises [5][6]. - The city’s industrial research institute has developed a detailed industrial chain map, identifying key enterprises and potential partners, which serves as a "research map" for attracting investment [4][7]. Group 2: Investment Attraction and Implementation - The research institute has established four selection criteria for attracting advanced medical device projects, focusing on those that address real clinical problems and possess significant technological barriers [7][8]. - A comprehensive strategy has been implemented, including the establishment of a 1 billion yuan medical device special fund and supportive policies covering the entire product lifecycle, to facilitate the attraction of key enterprises [8][9]. Group 3: New Model Development - Zigong is developing a replicable new model for investment attraction that emphasizes external expertise and internal collaboration, successfully attracting quality projects like Wolant and Jiushi Intelligent [9][10]. - The model is lightweight, focusing on research capabilities and resource integration rather than asset investment, making it suitable for small to medium-sized cities [10].

Core Insights - The core viewpoint of the article highlights the expected growth in revenue for China Huaneng in the strategic emerging industries sector by 2025, indicating a significant shift in the company's focus and potential market positioning [1] Group 1 - By 2025, China Huaneng's revenue in the strategic emerging industries is projected to reach 104.9 billion yuan [1] - The revenue share from these industries is expected to increase by 14.2 percentage points compared to 2022 [1]

Core Insights - The State-owned Assets Supervision and Administration Commission (SASAC) held a meeting on January 9 to discuss the deepening and enhancement of state-owned enterprise reforms [1] - Li Zhen, a member of the SASAC Party Committee and Deputy Director, reported that by November 2025, the operating revenue of central enterprises in strategic emerging industries is expected to exceed 11 trillion yuan [1] Group 1 - The meeting focused on the experiences and actions taken to reform state-owned enterprises [1] - The emphasis was placed on the performance of central enterprises in strategic emerging industries [1] - The projected revenue growth indicates a significant expansion in this sector [1]

Summary of Key Points Core Viewpoint - On January 9, 2023, New Industry experienced two block trades totaling 1.746 million shares and a transaction amount of 106 million yuan, with a transaction price of 60.50 yuan, reflecting a discount of 3.69% compared to the closing price of the day [2] Trading Activity - The total transaction amount for the two block trades was 106 million yuan, with an average transaction price of 60.50 yuan, which is 3.69% lower than the closing price [2] - In the last three months, New Industry has recorded four block trades with a cumulative transaction amount of 191 million yuan [2] Market Performance - The closing price of New Industry on January 9 was 62.82 yuan, marking an increase of 2.80% for the day, with a turnover rate of 0.53% and a total transaction amount of 224 million yuan [2] - The net inflow of main funds for the day was 8.2827 million yuan, and over the past five days, the stock has increased by 11.68% with a total net inflow of 12.237 million yuan [2] Margin Financing - The latest margin financing balance for New Industry is 805 million yuan, which has decreased by 134,900 yuan over the past five days, reflecting a decline of 0.02% [2]

Group 1 - The stock of New Industry increased by 2.80%, closing at 62.82 yuan, with two block trades totaling 1.06 billion yuan in transaction volume [1] - The first block trade occurred at a price of 60.50 yuan for 826,000 shares, amounting to 49.973 million yuan, with a premium rate of -3.69% [1] - The second block trade also occurred at 60.50 yuan for 920,000 shares, totaling 55.66 million yuan, with the same premium rate of -3.69% [1] Group 2 - In the last three months, the stock has recorded four block trades with a total transaction amount of 191 million yuan [1] - Over the past five trading days, the stock has risen by 11.68%, with a net inflow of 26.318 million yuan from main funds [1]

Group 1 - The core point of the article is the establishment of Anhui Ruijing Semiconductor Co., Ltd. with a registered capital of approximately 500 million yuan, focusing on semiconductor manufacturing [1] - The company's business scope includes the manufacturing of semiconductor discrete devices, semiconductor lighting devices, integrated circuits, and integrated circuit chips and products [1] - The ownership structure reveals that the company is jointly held by Hefei Fangjing Technology Co., Ltd. and Wuhu High-tech Industry Development Fund Co., Ltd. [1]

Core Viewpoint - The stock price of New Industry has shown a positive trend, with a year-to-date increase of 10.83%, indicating strong market interest and potential growth in the biomedical sector [2]. Group 1: Stock Performance - As of January 9, New Industry's stock price increased by 2.01%, reaching 62.34 CNY per share, with a trading volume of 66.98 million CNY and a turnover rate of 0.16% [1]. - The stock has experienced a 10.83% increase in price this year, with a 10.83% rise over the last five trading days and a 7.30% increase over the last 20 days, while it has slightly decreased by 0.45% over the last 60 days [2]. Group 2: Company Overview - New Industry, established on December 15, 1995, and listed on May 12, 2020, is based in Shenzhen, Guangdong Province, specializing in the research, development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents [2]. - The company's revenue composition is as follows: reagents account for 69.62%, instruments for 30.21%, and other sources for 0.16% [2]. Group 3: Financial Performance - For the period from January to September 2025, New Industry reported a revenue of 3.428 billion CNY, reflecting a year-on-year growth of 0.39%, while the net profit attributable to shareholders decreased by 12.92% to 1.205 billion CNY [2]. - Since its A-share listing, New Industry has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for New Industry was 13,100, a decrease of 15.87% from the previous period, with an average of 51,997 circulating shares per shareholder, an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 26.4824 million shares, an increase of 4.2383 million shares from the previous period, while other notable shareholders include Huabao Zhongzheng Medical ETF and Yifangda Blue Chip Selected Mixed Fund [3].

Group 1 - The provincial government emphasizes the integration of artificial intelligence with healthcare to meet the growing health service demands of the public [1] - The healthcare insurance information system is highlighted for its vast data capacity, which enhances service efficiency and ensures the safety of insurance funds [1] - The government aims to strengthen insurance fund supervision using AI technology to create a closed-loop system for risk prevention and control [1] Group 2 - The focus is on exploring AI-assisted medical classification standards and accelerating the development of intelligent systems for innovative applications [2] - Collaboration among industry, academia, and healthcare is encouraged to enhance the integration of AI with medical practices and improve the AI literacy of healthcare professionals [2] - The provincial government supports the growth of companies specializing in medical AI technologies, aiming to establish a stronghold for AI industry development in the region [2]